← All trials
NCT05187546
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 10, 2022
- Primary completion
- Jun 30, 2023
- Completion date
- Dec 31, 2023
- First posted
- Jan 12, 2022
- Last posted
- Dec 15, 2022
- Enrollment
- 15
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- PiramalLead sponsor
- Technical University of MunichOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.